Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This "Non Muscle ...
The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical ...
Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with ...
Program intended to facilitate CMC development for selected therapies with expedited clinical development timeframes to help patients get access sooner “At Bicycle Therapeutics, we are pioneering an ...
Stocktwits on MSN
SLS, IBRX, IOVA in focus amid big pharma’s early cancer-asset hunt: J&J flags M&A ‘sweet spot,’ Pfizer eyes phase 1-2 deals
SLS009 has shown 46%-50% response rates in AML and is being studied in KRAS-mutant pancreatic cancer. ・ImmunityBio’s Anktiva ...
NCCN 2026 Bladder Cancer Guidelines Adopt IBCG Risk Stratification Model for Intermediate-Risk NMIBC
The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results